Jan 05, 2021 / 05:35PM GMT
Salveen Jaswal Richter - Goldman Sachs Group, Inc., Research Division - VP
Good afternoon. Thanks for joining us. We're pleased to have Jean-Jacques Bienaimé, Chairman and CEO of BioMarin with us. And with that, J.J., I'm going to turn it over to you for any opening comments, and then we'll jump into Q&A.
Jean-Jacques Bienaime - BioMarin Pharmaceutical Inc. - Chairman & CEO
Thank you, Salveen. Good morning or good afternoon to everybody here. So 2020 was an eventful year for BioMarin, and we look forward to many important developments in 2021. So we were pleased to have announced 2 weeks ago that the benefit of treatment with vosoritide for achondroplasia was maintained for over 2 years in children treated in our Phase III study. A cumulative high gain -- height gain of 3.52 centimeters was observed at year 2 compared to untreated children.
So we are encouraged about the prospect of vosoritide approval this year based on these results. So I just want to highlight that actually -- it's likely since the patients are going to be
Biomarin Pharmaceutical Inc at Goldman Sachs Healthcare CEOs Unscripted Conference (Virtual) Transcript
Jan 05, 2021
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers